Floatz logo

Cefixime

Solid Tumor

Children's Hospital Medical Center, CincinnatiSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
59/ 100

Competitive context

928 Active assets in the Solid Tumor cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB
Relatlimab
Bristol-Myers Squibb
Phase 2BB

View all 50 →

Same molecule, other indications

Cefixime is also rated in:

cancer of unknown primary siteDormant
CC
Indicative ·
46 / 100
View asset →
Refractory Solid TumorsDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →